The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Andrew Grey

Department of Medicine

University of Auckland

Private Bag 92 019

Auckland

New Zealand

[email]@auckland.ac.nz

Name/email consistency: high

 
 
 
 
 
 
 

Affiliation

  • Department of Medicine, University of Auckland, Private Bag 92 019, Auckland, New Zealand. 2001 - 2012

References

  1. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. Grey, A., Bolland, M., Wong, S., Horne, A., Gamble, G., Reid, I.R. J. Clin. Endocrinol. Metab. (2012) [Pubmed]
  2. Decreased bone density in men on methadone maintenance therapy. Grey, A., Rix-Trott, K., Horne, A., Gamble, G., Bolland, M., Reid, I.R. Addiction (2011) [Pubmed]
  3. Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. Grey, A., Bolland, M., Wattie, D., Horne, A., Gamble, G., Reid, I.R. J. Bone Miner. Res. (2010) [Pubmed]
  4. Thiazolidinedione-induced skeletal fragility--mechanisms and implications. Grey, A. Diabetes. Obes. Metab (2009) [Pubmed]
  5. Skeletal consequences of thiazolidinedione therapy. Grey, A. Osteoporos. Int (2008) [Pubmed]
  6. Emerging pharmacologic therapies for osteoporosis. Grey, A. Expert. Opin. Emerg. Drugs (2007) [Pubmed]
  7. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., Reid, I.R. J. Clin. Endocrinol. Metab. (2007) [Pubmed]
  8. Lactoferrin potently inhibits osteoblast apoptosis, via an LRP1-independent pathway. Grey, A., Zhu, Q., Watson, M., Callon, K., Cornish, J. Mol. Cell. Endocrinol. (2006) [Pubmed]
  9. Calcium supplementation does not affect CRP levels in postmenopausal women--a randomized controlled trial. Grey, A., Gamble, G., Ames, R., Horne, A., Mason, B., Reid, I.R. Osteoporos. Int (2006) [Pubmed]
  10. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. Grey, A., Lucas, J., Horne, A., Gamble, G., Davidson, J.S., Reid, I.R. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  11. Emerging and potential therapies for osteoporosis. Grey, A., Reid, I.R. Expert. Opin. Investig. Drugs (2005) [Pubmed]
  12. The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Grey, A., Banovic, T., Zhu, Q., Watson, M., Callon, K., Palmano, K., Ross, J., Naot, D., Reid, I.R., Cornish, J. Mol. Endocrinol. (2004) [Pubmed]
  13. Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate. Grey, A., Xu, X., Hill, B., Watson, M., Callon, K., Reid, I.R., Cornish, J. Calcif. Tissue Int. (2004) [Pubmed]
  14. Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Grey, A., Chen, Q., Xu, X., Callon, K., Cornish, J. Endocrinology (2003) [Pubmed]
  15. The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase. Grey, A., Chen, Q., Callon, K., Xu, X., Reid, I.R., Cornish, J. Endocrinology (2002) [Pubmed]
  16. Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases. Grey, A., Banovic, T., Naot, D., Hill, B., Callon, K., Reid, I., Cornish, J. Endocrinology (2001) [Pubmed]
 
WikiGenes - Universities